# begin document 
0	Description	_
1	:	_
2	Posttransplant	_
3	lymphoproliferative	_
4	disorder	_
5	,	_
6	chronic	_
7	renal	_
8	insufficiency	_
9	,	_
10	squamous	_
11	cell	_
12	carcinoma	_
13	of	_
14	the	(1
15	skin	1)
16	,	_
17	anemia	_
18	secondary	_
19	to	_
20	chronic	_
21	renal	_
22	insufficiency	_
23	and	_
24	chemotherapy	_
25	,	_
26	and	_
27	hypertension	_
28	.	_
29	The	(2
30	patient	2)
31	is	_
32	here	_
33	for	_
34	followup	_
35	visit	_
36	and	_
37	chemotherapy	_
38	.	_
39	CHIEF	_
40	COMPLAINT	_
41	:	_
42	The	(2
43	patient	2)
44	is	_
45	here	_
46	for	_
47	followup	_
48	visit	_
49	and	_
50	chemotherapy	_
51	.	_
52	DIAGNOSES	_
53	:	_
54	1.	_
55	Posttransplant	(3
56	lymphoproliferative	_
57	disorder	3)
58	.	_
59	2.	_
60	Chronic	_
61	renal	_
62	insufficiency	_
63	.	_
64	3.	_
65	Squamous	_
66	cell	_
67	carcinoma	_
68	of	_
69	the	(1
70	skin	1)
71	.	_
72	4.	_
73	Anemia	_
74	secondary	_
75	to	_
76	chronic	_
77	renal	_
78	insufficiency	_
79	and	_
80	chemotherapy	_
81	.	_
82	5.	_
83	Hypertension	_
84	.	_
85	HISTORY	_
86	OF	_
87	PRESENT	_
88	ILLNESS	_
89	:	_
90	A	(2
91	51	_
92	-	_
93	year	_
94	-	_
95	old	_
96	white	_
97	male	_
98	diagnosed	_
99	with	_
100	PTLD	(3)
101	in	_
102	latter	_
103	half	_
104	of	_
105	2007	2)
106	.	_
107	He	(2)
108	presented	_
109	with	_
110	symptoms	_
111	of	_
112	increasing	_
113	adenopathy	_
114	,	_
115	abdominal	_
116	pain	_
117	,	_
118	weight	_
119	loss	_
120	,	_
121	and	_
122	anorexia	_
123	.	_
124	He	(2)
125	did	_
126	not	_
127	seek	_
128	medical	_
129	attention	_
130	immediately	_
131	.	_
132	He	(2)
133	was	_
134	finally	_
135	hospitalized	_
136	by	_
137	the	_
138	renal	_
139	transplant	_
140	service	_
141	and	_
142	underwent	_
143	a	_
144	lymph	_
145	node	_
146	biopsy	_
147	in	_
148	the	_
149	groin	_
150	,	_
151	which	_
152	showed	_
153	diagnosis	_
154	of	_
155	large	_
156	cell	_
157	lymphoma	_
158	.	_
159	He	(2)
160	was	_
161	discussed	_
162	at	_
163	the	_
164	hematopathology	_
165	conference	_
166	.	_
167	Chemotherapy	_
168	with	_
169	rituximab	_
170	plus	_
171	cyclophosphamide	_
172	,	_
173	daunorubicin	_
174	,	_
175	vincristine	_
176	,	_
177	and	_
178	prednisone	_
179	was	_
180	started	_
181	.	_
182	First	_
183	cycle	_
184	of	_
185	chemotherapy	_
186	was	_
187	complicated	_
188	by	_
189	sepsis	_
190	despite	_
191	growth	_
192	factor	_
193	support	_
194	.	_
195	He	(2)
196	also	_
197	appeared	_
198	to	_
199	have	_
200	become	_
201	disoriented	_
202	either	_
203	secondary	_
204	to	_
205	sepsis	_
206	or	_
207	steroid	_
208	therapy	_
209	.	_
210	The	(2
211	patient	2)
212	has	_
213	received	_
214	5	_
215	cycles	_
216	of	_
217	chemotherapy	_
218	to	_
219	date	_
220	.	_
221	He	(2)
222	did	_
223	not	_
224	keep	_
225	his	(2)
226	appointment	_
227	for	_
228	a	_
229	PET	_
230	scan	_
231	after	_
232	3	_
233	cycles	_
234	because	_
235	he	(2)
236	was	_
237	not	_
238	feeling	_
239	well	_
240	.	_
241	His	(2)
242	therapy	_
243	has	_
244	been	_
245	interrupted	_
246	for	_
247	infection	_
248	related	_
249	to	_
250	squamous	_
251	cell	_
252	cancer	_
253	,	_
254	skin	_
255	surgery	_
256	as	_
257	well	_
258	as	_
259	complaints	_
260	of	_
261	chest	_
262	infection	_
263	.	_
264	The	(2
265	patient	2)
266	is	_
267	here	_
268	for	_
269	the	_
270	sixth	_
271	and	_
272	final	_
273	cycle	_
274	of	_
275	chemotherapy	_
276	.	_
277	He	(2)
278	states	_
279	he	(2)
280	feels	_
281	well	_
282	.	_
283	He	(2)
284	denies	_
285	any	_
286	nausea	_
287	,	_
288	vomiting	_
289	,	_
290	cough	_
291	,	_
292	shortness	_
293	of	_
294	breath	_
295	,	_
296	chest	_
297	pain	_
298	or	_
299	fatigue	_
300	.	_
301	He	(2)
302	denies	_
303	any	_
304	tingling	_
305	or	_
306	numbness	_
307	in	_
308	his	(2)
309	fingers	_
310	.	_
311	Review	_
312	of	_
313	systems	_
314	is	_
315	otherwise	_
316	entirely	_
317	negative	_
318	.	_
319	Performance	_
320	status	_
321	on	_
322	the	_
323	ECOG	_
324	scale	_
325	is	_
326	1	_
327	PHYSICAL	_
328	EXAMINATION	_
329	:	_
330	VITAL	_
331	SIGNS	_
332	:	_
333	He	(2)
334	is	_
335	afebrile	_
336	.	_
337	Blood	_
338	pressure	_
339	161	_
340	/	_
341	80	_
342	,	_
343	pulse	_
344	65	_
345	,	_
346	weight	_
347	71.5	_
348	kg	_
349	,	_
350	which	_
351	is	_
352	essentially	_
353	unchanged	_
354	from	_
355	his	(2)
356	prior	_
357	visit	_
358	.	_
359	There	_
360	is	_
361	mild	_
362	pallor	_
363	noted	_
364	.	_
365	There	_
366	is	_
367	no	_
368	icterus	_
369	,	_
370	adenopathy	_
371	or	_
372	petechiae	_
373	noted	_
374	.	_
375	CHEST	_
376	:	_
377	Clear	_
378	to	_
379	auscultation	_
380	.	_
381	CARDIOVASCULAR	_
382	:	_
383	S1	_
384	and	_
385	S2	_
386	normal	_
387	with	_
388	regular	_
389	rate	_
390	and	_
391	rhythm	_
392	.	_
393	Systolic	_
394	flow	_
395	murmur	_
396	is	_
397	best	_
398	heard	_
399	in	_
400	the	_
401	pulmonary	_
402	area	_
403	.	_
404	ABDOMEN	_
405	:	_
406	Soft	_
407	and	_
408	nontender	_
409	with	_
410	no	_
411	organomegaly	_
412	.	_
413	Renal	_
414	transplant	_
415	is	_
416	noted	_
417	in	_
418	the	_
419	right	_
420	lower	_
421	quadrant	_
422	with	_
423	a	_
424	scar	_
425	present	_
426	.	_
427	EXTREMITIES	_
428	:	_
429	Reveal	_
430	no	_
431	edema	_
432	.	_
433	LABORATORY	_
434	DATA	_
435	:	_
436	CBC	(4)
437	from	_
438	today	_
439	shows	_
440	white	_
441	count	_
442	of	_
443	9.6	_
444	with	_
445	a	_
446	normal	_
447	differential	_
448	,	_
449	ANC	_
450	of	_
451	7400	_
452	,	_
453	hemoglobin	_
454	8.9	_
455	,	_
456	hematocrit	_
457	26.5	_
458	with	_
459	an	_
460	MCV	_
461	of	_
462	109	_
463	,	_
464	and	_
465	platelet	_
466	count	_
467	of	_
468	220,000	_
469	.	_
470	ASSESSMENT	_
471	AND	_
472	PLAN	_
473	:	_
474	1.	_
475	Diffuse	_
476	large	_
477	B	_
478	-	_
479	cell	_
480	lymphoma	_
481	following	_
482	transplantation	_
483	.	_
484	The	(2
485	patient	2)
486	is	_
487	to	_
488	receive	_
489	his	(2)
490	sixth	_
491	and	_
492	final	_
493	cycle	_
494	of	_
495	chemotherapy	_
496	today	_
497	.	_
498	PET	_
499	scan	_
500	has	_
501	been	_
502	ordered	_
503	to	_
504	be	_
505	done	_
506	within	_
507	2	_
508	weeks	_
509	.	_
510	He	(2)
511	will	_
512	see	_
513	me	_
514	back	_
515	for	_
516	the	_
517	visit	_
518	in	_
519	3	_
520	weeks	_
521	with	_
522	CBC	(4)
523	,	_
524	CMP	(5)
525	,	_
526	and	_
527	LDH	_
528	.	_
529	2.	_
530	Chronic	_
531	renal	_
532	insufficiency	_
533	.	_
534	3.	_
535	Anemia	_
536	secondary	_
537	to	_
538	chronic	_
539	renal	_
540	failure	_
541	and	_
542	chemotherapy	_
543	.	_
544	He	(2)
545	is	_
546	to	_
547	continue	_
548	on	_
549	his	(2)
550	regimen	_
551	of	_
552	growth	_
553	factor	_
554	support	_
555	.	_
556	4.	_
557	Hypertension	(6)
558	.	_
559	This	(6)
560	is	_
561	elevated	_
562	today	_
563	because	_
564	he	(2)
565	held	(7)
566	his	(2)
567	meds	_
568	because	_
569	he	(2)
570	is	_
571	getting	_
572	rituximab	_
573	other	_
574	than	_
575	that	(7)
576	this	(6)
577	is	_
578	well	_
579	controlled	_
580	.	_
581	His	(5(2)
582	CMP	5)
583	is	_
584	pending	_
585	from	_
586	today	_
587	.	_
588	5.	_
589	Squamous	_
590	cell	_
591	carcinoma	_
592	of	_
593	the	_
594	skin	_
595	.	_
596	The	_
597	scalp	_
598	is	_
599	well	_
600	healed	_
601	.	_
602	He	(2)
603	still	_
604	has	_
605	an	(8
606	open	_
607	wound	_
608	on	_
609	the	_
610	right	_
611	posterior	_
612	aspect	_
613	of	_
614	his	(2)
615	trunk	8)
616	.	_
617	This	(8)
618	has	_
619	no	_
620	active	_
621	drainage	_
622	,	_
623	but	_
624	it	(8)
625	is	_
626	yet	_
627	to	_
628	heal	_
629	.	_
630	This	(8)
631	probably	_
632	will	_
633	heal	_
634	by	_
635	secondary	_
636	intention	_
637	once	_
638	chemotherapy	(9)
639	is	_
640	finished	_
641	.	_
642	Prescription	_
643	for	_
644	prednisone	_
645	as	_
646	part	_
647	of	_
648	his	(9(2)
649	chemotherapy	9)
650	has	_
651	been	_
652	given	_
653	to	_
654	him	(2)
655	.	_
# end document
